EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Nanozyme‐Mediated Cellular and Microenvironmental Metabolic Reprogramming for Boosting Cancer Immunotherapy

Bili Zhang, Menghuan Li, Yan Hu iD, Yingqi Liu, Zhong Luo iD

Small · 2026-09 · 22 (51)

DOI: 10.1002/smll.74869 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Small, online erschienen am 04.08.2026. Verfasst von Bili Zhang und 4 weiteren Autor:innen. Beteiligte Einrichtung: School of Life Science, Chongqing University, Chongqing, China. Hauptthemen laut MEDLINE: Immunotherapy, Tumor Microenvironment, Neoplasms. Die Arbeit nennt 167 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National Natural Science Foundation of China, Fundamental Research Funds for the Central Universities, Fundamental Research Funds for the Key Research Program of Chongqing Science and Technology Commission.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The effectiveness of cancer immunotherapy is often compromised by a highly immunosuppressive tumor microenvironment (TME), characterized by pro‐tumorigenic metabolic abnormalities including hypoxia, nutrient competition, and accumulation of toxic metabolites. Here, we review the potential of nanozymes to directly modulate immunometabolic pathways to empower immunotherapeutic efficacy. We describe how nanozymes with distinct catalytic properties can reprogram the TME to alleviate hypoxia, supplement nutrients, and eliminate immunosuppressive metabolites such as glutathione and kynurenine. The nanozyme‐enabled biocatalytic remodeling of tumor immunometabolic landscape enhances the function and maturation of antigen‐presenting cells (APCs) while blocking immunosuppressive cells such as regulatory T cells (Tregs) and myeloid‐derived suppressor cells (MDSCs), leading to the restoration of metabolic fitness of antitumorigenic T cells. Furthermore, we explore the synergy of nanozymes with established immunotherapeutics such as immune checkpoint inhibitors (ICB), adoptive cell therapies, and cancer vaccines. Finally, we address the challenges of translating these findings into clinical practice and propose future directions for integrating these nanozyme‐based strategies into innovative combination therapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ImmunotherapyTumor MicroenvironmentNeoplasmsHumansMetabolic ReprogrammingAnimals

Stichwörter der Autor:innen

cancer immunotherapiescombination therapyimmunometabolismnanozymestumor microenvironment

Autor:innen und Institutionen

  • School of Life Science, Chongqing University, Chongqing, China.
  • Key Laboratory of Biorheological Science and Technology, Ministry of Education, College of Bioengineering, Chongqing University, Chongqing, China.

ORCID-Profile: Yan Hu, Zhong Luo

Förderung

  • National Natural Science Foundation of China
  • Fundamental Research Funds for the Central Universities
  • Fundamental Research Funds for the Key Research Program of Chongqing Science and Technology Commission

Zitieren

APA

Zhang, B., Li, M., Hu, Y., Liu, Y., & Luo, Z. (2026). Nanozyme‐Mediated Cellular and Microenvironmental Metabolic Reprogramming for Boosting Cancer Immunotherapy. Small, 22(51). https://doi.org/10.1002/smll.74869

Vancouver

Zhang B, Li M, Hu Y, Liu Y, Luo Z. Nanozyme‐Mediated Cellular and Microenvironmental Metabolic Reprogramming for Boosting Cancer Immunotherapy. Small. 2026;22(51). doi:10.1002/smll.74869

BibTeX
@article{Zhang2026,
  author = {Zhang, Bili and Li, Menghuan and Hu, Yan and Liu, Yingqi and Luo, Zhong},
  title = {Nanozyme‐Mediated Cellular and Microenvironmental Metabolic Reprogramming for Boosting Cancer Immunotherapy},
  journal = {Small},
  year = {2026},
  volume = {22},
  number = {51},
  doi = {10.1002/smll.74869}
}
Kostenlos starten →